The Pharmaceuticals Export Promotion Council of India (Pharmexcil), established under the ministry of commerce and industry, Government of India, has initiated the enrolment process for eligible voters in the upcoming 2024-26 Committee of Administration (CoA) elections. This process marks the beginning of a crucial period in determining the leadership responsible for shaping the future of India’s pharmaceutical exports.
The voter enrolment process is now open, with the final date for submissions set as November 30, 2024. The elections will empower members to select representatives tasked with addressing industry challenges, promoting export opportunities, and fostering global competitiveness in the pharmaceutical sector.
Eligibility to vote is governed by Pharmexcil’s model bye-laws, which stipulate the following requirements:
Ordinary members must meet specific export turnover criteria based on the previous two financial years for micro enterprises at Rs. 25 lakhs (average exports), small enterprises at Rs. 50 lakhs (average exports), medium enterprises at Rs. 1 crore (average exports), non-MSMEs at exports exceeding Rs. 1 crore (average).
For associate members, membership of three continuous years is required.
The entity must have achieved an average export turnover of Rs. 25 lakhs over the preceding three financial years. General requirements for all members include membership renewal for the financial year 2023-24 is mandatory.
Eligible members are encouraged to complete their enrolment as early as possible by submitting the necessary documents to Pharmexcil. This step is vital for those wishing to vote and contribute to electing a leadership that can effectively navigate the pharmaceutical industry’s evolving landscape.
The Committee of Administration elections are more than a procedural formality. They represent a unique opportunity for members to influence the Council’s priorities and strategies. By voting, members play a direct role in empowering the industry to address global challenges, access untapped markets, and strengthen India’s position as a leading pharmaceutical exporter.
|